Submission Details
| 510(k) Number | K181324 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | May 18, 2018 |
| Decision Date | November 15, 2018 |
| Days to Decision | 181 days |
| Submission Type | Traditional |
| Review Panel | Microbiology (MI) |
| Summary | Summary PDF |
K181324 is an FDA 510(k) clearance for the FilmArray Pneumonia Panel plus, a Mers-cov And Common Respiratory Pathogens Semi-quantitative And Quantitative Multiplex Nucleic Acid Detection System (Class II — Special Controls, product code QDS), submitted by Biofire Diagnostics, LLC (Salt Lake City, US). The FDA issued a Cleared decision on November 15, 2018, 181 days after receiving the submission on May 18, 2018. This device falls under the Microbiology review panel. Regulated under 21 CFR 866.4001.
| 510(k) Number | K181324 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | May 18, 2018 |
| Decision Date | November 15, 2018 |
| Days to Decision | 181 days |
| Submission Type | Traditional |
| Review Panel | Microbiology (MI) |
| Summary | Summary PDF |
| Product Code | QDS — Mers-cov And Common Respiratory Pathogens Semi-quantitative And Quantitative Multiplex Nucleic Acid Detection System |
| Device Class | Class II — Special Controls |
| CFR Regulation | 21 CFR 866.4001 |
| Definition | A Middle East Respiratory Syndrome Coronavirus (mers-cov) And Common Respiratory Pathogens Qualitative, Semi-quantitative Or Quantitative Multiplex Nucleic Acid Detection System Is An In Vitro Diagnostic Test For The Detection, Identification, And Quantification Of Mers-cov And Common Respiratory Pathogens ? Associated Nucleic Acids In Human Clinical Specimens. The Test Is Indicated For Individuals Meeting Specific Mers-cov Clinical And/or Epidemiological Criteria. It Aids In The Differential Diagnosis Of Mers-cov Infection In Conjunction With Other Clinical, Epidemiologic, And Laboratory Data, In Accordance With The Guidelines Provided By The Appropriate Public Health Authorities. |